Corium is a commercial-stage biopharmaceutical company leading the development of new transdermal healthcare products that provide clinicians with important treatment options for patients and their families.
Corium, Inc. Announces FDA Filing Acceptance of New Drug Application for ADLARITY® (donepezil transdermal system) for the Treatment of Alzheimer’s Disease
MENLO PARK, Calif., January 27, 2020 (GLOBE NEWSWIRE) – Corium, Inc., a commercial-stage biopharmaceutical company leading the development of novel transdermal healthcare products that are intended to provide alternative treatment options for patients and their families, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s New Drug Application (NDA) for ADLARITY (donepezil transdermal system), its lead investigational agent for the treatment of dementia of the Alzheimer’s type in patients with mild, moderate, and severe Alzheimer’s disease…
Apr 02, 2019
Corium Appoints Perry Sternberg as Chief Executive Officer
MENLO PARK, Calif., April 2, 2019 (GLOBE NEWSWIRE) – Corium, Inc. announced today that its Board of Directors has named Perry Sternberg as Chief Executive Officer. Mr. Sternberg is a senior pharmaceutical executive with commercial experience across a wide range of therapeutic areas in diverse markets…
OUR LEAD INVESTIGATIONAL PRODUCT
Our lead product is an investigational transdermal formulation of donepezil, the active ingredient in Aricept™. Donepezil is one of the most commonly prescribed treatments for the care of patients with Alzheimer’s disease. Corplex Donepezil is designed to provide sustained and controlled delivery of donepezil. It is being investigated as a once-weekly treatment for Alzheimer’s disease to deliver either 5mg or 10mg of donepezil per 24 hours over a one-week period, with a pharmacokinetic (PK) profile comparable to oral Aricept taken daily for seven days. Learn more
The safety and efficacy of Corplex Donepezil has not been established. There is no assurance that the product will receive health authority approval or become commercially available in any country.